Skip to main content

Advertisement

Table 9 TEAEs by age group in the crossover phase while receiving LDX with an incidence of ≥10% in the dose-optimization and/or crossover phase

From: Efficacy and tolerability of lisdexamfetamine dimesylate in children with attention-deficit/hyperactivity disorder: sex and age effects and effect size across the day

AE-Preferred Term Crossover Phase
  6 to 9 year olds 10 to 12 year olds
  (n = 42) (n = 73)
  n (%) n (%)
Any AE 16 (38.1) 22 (30.1)
Abdominal pain upper 1 (2.4) 1 (1.4)
Affect lability 0 (0.0) 0 (0.0)
Anorexia 0 (0.0) 0 (0.0)
Decreased appetite 2 (4.8) 5 (6.8)
Headache 2 (4.8) 4 (5.5)
Insomnia 3 (7.1) 2 (2.7)
Irritability 1 (2.4) 0 (0.0)